Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study

Yao Junlin; Wang Zhengyang; Sheng Jin; Wang Huadi; You Liangkun; Zhu Xudong; Pan Hongming; Han Weidong

首页> 外文期刊>International immunopharmacology >Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study

【24h】

Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study

机译：联合免疫治疗和抗血管生成治疗晚期非小细胞肺癌的疗效和安全性：双中心回顾性研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The synergistic effects of immunotherapy and antiangiogenic therapy in advanced non-small cell lung cancer (NSCLC) have been reported in both preclinical and clinical trials. Herein, we evaluated the preliminary efficacy and safety of combined immunotherapy and antiangiogenic therapy in patients with previously treated advanced NSCLC in a real-world setting.

机译：None

著录项

来源
《International immunopharmacology》 |2020年第1期|共8页
作者
Yao Junlin; Wang Zhengyang; Sheng Jin; Wang Huadi; You Liangkun; Zhu Xudong; Pan Hongming; Han Weidong;
展开▼
作者单位

Zhejiang Univ Sir Run Run Shaw Hosp Dept Med Oncol Coll Med Hangzhou 310016 Zhejiang Peoples;

Zhejiang Univ Sir Run Run Shaw Hosp Dept Resp Med Coll Med Hangzhou 310016 Zhejiang Peoples R;

Zhejiang Univ Sir Run Run Shaw Hosp Dept Med Oncol Coll Med Hangzhou 310016 Zhejiang Peoples;

Zhejiang Univ Sir Run Run Shaw Hosp Dept Med Oncol Coll Med Hangzhou 310016 Zhejiang Peoples;

Zhejiang Univ Sir Run Run Shaw Hosp Dept Med Oncol Coll Med Hangzhou 310016 Zhejiang Peoples;

Zhejiang Univ Affiliated Hosp 1 Dept Med Oncol Coll Med Hangzhou 310016 Zhejiang Peoples R;

Zhejiang Univ Sir Run Run Shaw Hosp Dept Med Oncol Coll Med Hangzhou 310016 Zhejiang Peoples;

Zhejiang Univ Sir Run Run Shaw Hosp Dept Med Oncol Coll Med Hangzhou 310016 Zhejiang Peoples;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Immunotherapy; Antiangiogenic therapy; Non-small cell lung cancer (NSCLC); Retrospective study;

机译：免疫疗法;抗血管生成治疗;非小细胞肺癌（NSCLC）;回顾性研究;

相似文献

外文文献
中文文献
专利

1. Assessment of the efficacy and safety of bronchial artery perfusion chemotherapy combined with high-frequency hyperthermia for advanced non-small cell lung cancer [J] . Jia-Cheng Zhang, Wei Lu 海南医科大学学报（英文版） . 2017,第011期
2. Assessment of the efficacy and safety of bronchial artery perfusion chemotherapy combined with high-frequency hyperthermia for advanced non-small cell lung cancer [J] . Jia-Cheng Zhang, Wei Lu 海南医科大学学报(英文版) . 2017,第011期
3. Clinical study on concurrent and sequential therapy of intensity modulated radiation therapy （IMRT） combined with NP regimen chemotherapy in the treatment of middle and advanced non-small cell lung cancer [J] . Xiaodong, Jiang, Da＇an, 中德临床肿瘤学杂志：英文版 . 2007,第001期
4. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC) [J] . Ziyi Xu, Teng Li, Xingsheng Hu, Thoracic cancer. . 2021,第17期

机译：将编程的细胞死亡-1（PD-1）抑制剂和抗血管生成靶向剂组合的功效和安全性曲线作为晚期或转移性非小细胞肺癌（NSCLC）的后续治疗
5. Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study [J] . Enomoto Yasunori, Kenmotsu Hirotsugu, Watanabe Naohiro, Anticancer Research: International Journal of Cancer Research and Treatment . 2015,第7期

机译：卡铂，紫杉醇和贝伐单抗联合治疗晚期非鳞状非小细胞肺癌合并间质性肺疾病的疗效和安全性：一项回顾性多机构研究
6. Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study [J] . Xu Xiangwei, Li Ruya, Zhu Peizhen, World Journal of Surgical Oncology . 2021,第1期

机译：高级非小细胞肺癌维持治疗的临床疗效和安全性：回顾性真实研究
7. Radiomics Biomarkers from PET/CT Multi-modality Fusion Images for the Prediction of Immunotherapy Response in Advanced Non-small Cell Lung Cancer Patients [C] . Wei Mu, Jin Qi, Hong Lu, SPIE Medical Imaging Conference . 2018

机译：PET / CT多模态融合图像的放射性标记生物标志物用于预测晚期非小细胞肺癌患者的免疫治疗反应
8. Symptoms Leading to Nutritional Risk in Advanced Non-Small Cell Lung Cancer Patients: The Importance of Nutritional Screening in the Advanced Lung Cancer Population [D] . Swinton, Nelda. 2009

机译：导致晚期非小细胞肺癌患者营养风险的症状：在晚期肺癌人群中进行营养筛查的重要性
9. Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study [O] . Shengjie Yang, Wenjie Zhang, Qing Chen, 2020

机译：Anlotinib在晚期非小细胞肺癌中嗜酸性能和安全性的临床调查作为第三线治疗：回顾性研究
10. Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer [O] . Martin Metzenmacher, Daniel C. Christoph 2016

机译：Nivolumab的功效和安全性结合高级小细胞肺癌一线治疗标准疗法
11. FLT-PET/CT as a Biomarker of Therapeutic Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer. [R] . Katz, S. I. 2016

机译：FLT-pET / CT作为培美曲塞治疗非小细胞肺癌治疗反应的生物标志物。

Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study

摘要

著录项

相似文献

相关主题

期刊订阅